Cel Sci (CVM) Return on Sales (2010 - 2017)
Cel Sci (CVM) posted Return on Sales of 2.78% for Q2 2017, down 507.72% sequentially from 0.46% in Q2 2016, and down 232.0% YoY from 2.1% in Q2 2016.
Cel Sci (CVM) Return on Sales (2010 - 2017) Analysis & Trends
Cel Sci has reported Return on Sales for 4 years, with the latest figure at 2.78% in Q2 2017.
- Quarterly Return on Sales fell 232.0% year-over-year to 2.78% in Q2 2017, while the trailing twelve-month figure through Jun 2017 was 0.67% (down 19.0% YoY) and the FY2011 annual result came in at 0.38%, up 158.0% from the prior year.
- Return on Sales slipped to 2.78% in Q2 2017 per CVM's latest filing, from 0.46% in the prior quarter.
- Over five years, Return on Sales peaked at 0.46% in Q2 2016 and troughed at 2.78% in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 0.00% |
| 10 | Cel Sci | 2.16 Mn | -4.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -2.78% |
| Jun 30, 2016 | -0.46% |
| Sep 30, 2011 | -0.22% |
| Jun 30, 2011 | -0.40% |
| Sep 30, 2010 | -0.36% |